首页 › 特应性皮炎(湿疹) › 印第安纳州 › Indianapolis
Indianapolis IN 特应性皮炎(湿疹)临床试验
7项针对 特应性皮炎(湿疹)的研究正在 Indianapolis及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
招募中1 期欢迎健康志愿者
- Clinical Site 106, Plainfield · 距离 14 英里
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
招募中3 期
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
招募中2 期
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
招募中2 期
- Enveda Investigative Site, Indianapolis
- Enveda Investigative Site, Plainfield · 距离 14 英里
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
招募中3 期
- Dawes Fretzin /ID# 265097, Indianapolis
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
招募中2 期
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
招募中观察性研究
- Galderma Investigational Site 8142, Indianapolis
其他城市的 特应性皮炎(湿疹)试验
- New York City, NY13 项研究
- Los Angeles, CA11 项研究
- Washington, DC11 项研究
- San Antonio, TX10 项研究
- San Diego, CA10 项研究
- Miami, FL9 项研究
- Birmingham, AL9 项研究
- Dallas, TX8 项研究
- Huntington Beach, CA8 项研究
- Sacramento, CA8 项研究
- Troy, MI8 项研究
- Tampa, FL7 项研究
Indianapolis的其他研究
- 非小细胞肺癌32 项研究
- 癌症(所有类型)24 项研究
- 心力衰竭23 项研究
- 肥胖症20 项研究
- 乳腺癌20 项研究
- 转移性癌症19 项研究
- 结直肠癌18 项研究
- 卵巢癌17 项研究
- 心血管疾病17 项研究
- 肺癌16 项研究
- 1型糖尿病14 项研究
- 子宫内膜癌14 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。